Nakamura, Mashio
Sakon, Masato
Sasako, Mitsuru
Okusaka, Takuji
Mukai, Hirofumi
Fujiwara, Keiichi
Kunitoh, Hideo
Oba, Mari S.
Wada, Hideo
Hosokawa, Jun
Takita, Atsushi
Ikeda, Masataka
Funding for this research was provided by:
Daiichi-Sankyo
Article History
Received: 25 October 2023
Accepted: 10 January 2024
First Online: 2 March 2024
Declarations
:
: Mashio Nakamura, Hirofumi Mukai, and Hideo Kunitoh received honoraria from Daiichi Sankyo Co., Ltd. Jun Hosokawa and Atsushi Takita are employees of Daiichi Sankyo Co., Ltd. Masataka Ikeda received honoraria and research funding from Daiichi Sankyo Co., Ltd. Masato Sakon, Mitsuru Sasako, Takuji Okusaka, Keiichi Fujiwara, Mari S. Oba, and Hideo Wada has no COI to be declared.
: The study adhered to the Declaration of Helsinki and the Ethical Guidelines for Medical and Health Research Involving Human Subjects by the Japanese Ministry of Health, Labour and Welfare. The Non-Profit Organization Clinical Research Promotion Network Japan approved the protocol (approval number: not applicable). Written informed consent were obtained from all patients. The Cancer-VTE Registry was registered at UMIN Clinical Trials Registry under the identifier number UMIN000024942.